Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease[7] and Pompe disease.[10]
It was approved for medical use in the European Union in November 2002,[7][11] and for medical use in the United States in July 2003.[12][13]
^"Miglustat (Zavesca) Use During Pregnancy". Drugs.com. 4 February 2020. Archived from the original on 28 November 2020. Retrieved 7 August 2020.
^"Summary for ARTG Entry:122957 Zavesca miglustat 100 mg capsules blister pack". Therapeutic Goods Administration.[permanent dead link]
^"Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 25 February 2021. Retrieved 7 August 2020.
^"Zavesca- miglustat capsule". DailyMed. 20 April 2023. Retrieved 2 October 2023.
^"Yargesa- miglustat capsule". DailyMed. 12 July 2023. Retrieved 2 October 2023.
^ abc"Zavesca EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 August 2020. Retrieved 7 August 2020.
^"Opfolda EPAR". European Medicines Agency (EMA). 7 July 2023. Retrieved 7 July 2023.
^"Yargesa EPAR". European Medicines Agency. 11 April 2023. Retrieved 2 October 2023.
^Cite error: The named reference Opfolda: Pending EC decision was invoked but never defined (see the help page).
^European Medicines Agency. Human Medicines Database. Zavesca (miglustat) Archived 7 January 2016 at the Wayback Machine Page Accessed 1 September 2014.
^"Drug Approval Package: Zavesca (Miglustat) NDA #021348". U.S. Food and Drug Administration (FDA). 4 April 2002. Archived from the original on 27 February 2021. Retrieved 9 August 2020.
^Actelion Press Release August 2003. Zavesca approved -- first oral treatment option for type 1 Gaucher disease Archived 3 March 2016 at the Wayback Machine
Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease. It was approved for...
glucocerebroside. It is classified under EC 2.4.1.80. It is inhibited by miglustat and eliglustat, both drugs developed for the treatment of Gaucher disease...
alfa, sold under the brand name Pombiliti, and used in combination with miglustat, is a medication used for the treatment of glycogen storage disease type...
1% of patients. No clinical interaction studies have been conducted. Miglustat appears to increase the clearance of imiglucerase by 70%, resulting in...
a drug against type 2 diabetes. Miglustat is an iminosugar in which the ring oxygen is replaced by nitrogen. Miglustat a drug used to treat some rare lysosomal...
metabolized and is excreted by the kidneys. Alpha-glucosidase inhibitor Miglustat Voglibose "Migliotl: MedlinePlus Drug Information". MedlinePlus. National...
two-component therapy of Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules for adults living with late-onset Pompe disease weighing...
decreased sperm production, but this effect was permanent in 20% of people. Miglustat (Zavesca or NB-DNJ) is a drug approved for treatment of several rare lipid...
receptor antagonist, see also: Endothelin receptor antagonist. Zavesca (miglustat): is currently the only approved oral treatment for patients with mild...
February 2018 the FDA accepted it and promised a response by August 2018. Miglustat, a drug for the treatment of Gaucher disease, with a similar structure...
medicines, N-hydroxyethyl-DNJ (miglitol) for diabetes and N-butyl-DNJ (miglustat) for Gaucher's disease. Anti-cancer and anti-viral activity was subsequently...
effective in treating lysosomal diseases. She managed to get the drug (Miglustat) approved by the European Medicines Agency and Food and Drug Administration...
β-glucocerebrosidase for enzyme replacement therapy of Gaucher's disease Miglustat, another orphan drug for the treatment of Gaucher's disease with a different...
include treatment with the drug OGT 918 (Zavesca). Gaucher's disease. Miglustat and eliglustat are substrate reduction therapies for Gaucher's disease...
Global Information
